Webinar | Completion of the Pediatric Praziquantel Consortium’s pivotal Phase III trial
8 Dec 2021 13:00-15:00 CET
Virtual event
Join the Pediatric Praziquantel Consortium in celebration on the major achievement of the completion of the pivotal clinical Phase III trial of arpraziquantel – a potential new treatment option for the estimated 50 million preschool-aged children with schistosomiasis.
Agenda
- Bert Leufkens, Pediatric Praziquantel Consortium Board member and Scientific Lead, Lygature - Welcome and introduction
- Peter Guenter, Member of the Executive Board of Merck and CEO Healthcare - Keynote address via video message: Harnessing the power of innovation and partnership to eliminate schistosomiasis
- Jutta Reinhard-Rupp, Head of the Global Health Institute at Merck, and Pediatric Praziquantel Consortium Board Chair - The Pediatric Praziquantel Consortium: Its history and journey to success
- Benjamin Dälken, Senior Director, Global Program Lead Immunology & Global Health at Merck - Results of the Pivotal Clinical Phase III Study
- Eliézer Kouakou N’Goran, Côte d’Ivoire Principal Investigator - Clinical trial experiences in Côte d’Ivoire
- Peter Steinmann, Swiss TPH - The Pediatric Praziquantel Consortium ADOPT Program
- Bert Leufkens, Pediatric Praziquantel Consortium Board member and Scientific Lead, Lygature - Q&A with questions from audience
- Michael Makanga, CEO of EDCTP - Closing remarks
Research